Méthotrexate dans l'arthrose inflammatoire érosive de la main (MERINO)
Essai sur le méthotrexate dans l'arthrose inflammatoire érosive (MERINO) : essai randomisé contrôlé par placebo visant à évaluer l'efficacité clinique et l'innocuité du méthotrexate dans l'arthrose inflammatoire érosive de la main.
A placebo-controlled randomized controlled trial exploring the effect of methotrexate on pain, function and structural outcomes in erosive inflammatory hand osteoarthritis.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
The trial will include Norwegian adult males and females with symptomatic erosive inflammatory hand osteoarthritis.
Participants will be randomized 1:1 to either:
- Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks (intervention group). Dosage can be reduced to as low as 10 mg if higher doses are not tolerated.
- Placebo (control group).
Both arms will receive folic acid 1mg daily.
The treatment duration for both groups is 52 weeks.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
-
Oslo, Norvège
- Diakonhjemmet Hospital
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Finger joint pain 40-80 on 0-100 visual analog scale (VAS) with insufficient pain relief from, inability to tolerate or contra-indications to oral paracetamol and/or NSAIDs, and hand symptoms (pain, aching, or stiffness) on most days the previous 6 weeks before randomization.
- Hand OA according to the American College of Rheumatology (ACR) criteria, at least 1 distal (DIP) or proximal interphalangeal (PIP) joint of the 2nd-5th finger with radiographic pre-erosive (J-phase) or erosive disease (E-phase) according to the Verbruggen-Veys anatomical phase system, and at least two DIP/PIP joints with power Doppler signal of at least grade 1 or grey-scale synovitis of at least grade 2 on ultrasound.
Exclusion Criteria:
A full list of the exclusion criteria for this study comprised the following:
-
Contraindications to methotrexate:
- Abnormal renal function, defined as serum creatinine >142 µmol/L in women and >168 µmol/L in men, or a glomeruli filtration rate (GFR) <40 mL/min/1.73 m2.
- Abnormal liver function, defined as transaminases above the upper normal limit, active or previous hepatitis B or C infection, or known cirrhosis
- Lung fibrosis (maximum 6 months old x-ray), active infection, or reduced hematopoiesis (i.e. anemia, leukopenia and/or thrombocytopenia).
- Planned pregnancy within 18 months after screening (men/women), and pregnancy, breastfeeding, or insufficient anti-conception therapy for female fertile participants. Contraception should be maintained during treatment and until the end of systemic exposure, i.e. 3 months after methotrexate discontinuation. Sufficient anti-conception therapy consists of intra-uterine device (coil) or hormonal anti-conception (birth control pills, implant, intra-uterine system, dermal patch, vaginal ring, or injections).
- Alcohol or other drug abuse in the last year.
- Intolerance to lactose.
-
Chronic inflammatory rheumatic diseases (such as rheumatoid arthritis and psoriatic arthritis or gout), active inflammatory bowel disease, or positive rheumatoid factor or anti-CCP antibodies.
-
Other severe co-morbidities such as hemochromatosis, fibromyalgia, psoriasis, blood dyscrasias, and coagulation disorders, history of malignancy (except successfully treated squamous or basal cell skin carcinoma), uncontrolled diabetes mellitus, severe hypertension, unstable ischemic heart disease, severe heart failure, severe pulmonary disease, severe and/or opportunistic infections and/or chronic infections, active tuberculosis, positive human immunodeficiency virus (HIV) status, recent stroke, bone marrow hypoplasia, or demyelinating diseases of the central nervous system.
-
Other likely causes of hand symptoms: thoracic outlet syndrome, carpal tunnel disease, diabetic cheiropathy, injury in finger joints previous 6 months, or palmar tenosynovitis/trigger finger.
-
Oral or intra-muscular steroids in the previous month
-
Intra-articular treatments or aspirations of any kind of any joint in the hands 3 months before inclusion
-
Analgesics or NSAIDs, unless stable dosage for ≥1 month.
-
Symptomatic slow-acting drugs for OA (SYSADOA), unless stable dose for ≥3 months and require stable dose throughout the study.
-
Disease-modifying osteoarthritis drugs (DMOADs) previous three months.
-
Scheduled hand surgery during study participation.
-
Planning to start other treatments for hand OA in the study participation period.
-
Not able to adhere to the study visit schedule and protocol requirements.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Comparateur actif: Methotrexate
Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks. Additional Folic acid 1mg prescribed daily. |
Methotrexate 2.5mg oral tablet. Folic acid |
|
Comparateur placebo: Placebo
3 capsules per week for two weeks, followed by 4 capsules the remaining weeks. Additional Folic acid 1mg prescribed daily. |
Placebo capsule Folic acid |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Finger pain on a visual analogue scale
Délai: 6 months
|
Difference in self-reported finger joint pain previous 48 hours on a 0-100 mm scale at 6 months of treatment; higher value indicate worse outcome. |
6 months
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Finger pain on a visual analogue scale
Délai: Month 1, 3, 9 and 12.
|
Self-reported finger pain previous 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 9 and 12.
|
|
Thumb pain on a visual analogue scale
Délai: Month 1, 3, 6, 9 and 12.
|
Self-reported thumb pain previous 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Pain most painful finger joint on a visual analogue scale
Délai: Month 1, 3, 6, 9 and 12.
|
Pain most painful finger joint last 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Patient-reported disease activity on a visual analogue scale
Délai: Month 1, 3, 6, 9 and 12.
|
Patient-reported disease activity last 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Pain all joints on a visual analogue scale
Délai: Month 1, 3, 6, 9 and 12.
|
Pain all joints last 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Hand diagram pain
Délai: Month 6.
|
Finger pain and thumb base pain (yes/no) on hand diagram |
Month 6.
|
|
Body diagram pain
Délai: Month 6.
|
Pain in other joints (yes/no) on body diagram |
Month 6.
|
|
AUSCAN
Délai: Month 1, 3, 6, 9 and 12.
|
Australian/Canadian hand index (AUSCAN), sum score 0-60, higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
OMERACT-OARSI responder criteria
Délai: Month 1, 3, 6, 9 and 12.
|
Fulfillment of Outcome Measures in Rheumatology Osteoarthritis Research Society International (OMERACT-OARSI) responder criteria. |
Month 1, 3, 6, 9 and 12.
|
|
EQ-5D
Délai: Month 1, 3, 6, 9 and 12.
|
Quality-adjusted life years (QALYs) based on the health-related utility scores measured by the generic instrument EuroQol 5 dimensions (EQ-5D), sum score 5-35, higher value indicate worse outcome, in addition to a 0-100 visual analogue scale where higher value indicate better outcome. |
Month 1, 3, 6, 9 and 12.
|
|
MHOQ
Délai: Month 6.
|
Michigan Hand Outcomes Questionnaire (MHOQ) pain and physical function subscales; function subscale range 10-50, higher value indicate worse outcome; task subscale range 17-85, higher value indicate worse outcome; work subscale range 5-25, higher value indicate worse outcome; pain subscale range 10-48, higher value indicate better outcome. |
Month 6.
|
|
Grip strength
Délai: Month 1, 3, 6, 9 and 12.
|
Grip strength (in kg; using a hand dynamometer) |
Month 1, 3, 6, 9 and 12.
|
|
HOOS-12
Délai: Month 6.
|
Hip disability and Osteoarthritis Outcome Score (HOOS)-12, range 12-60, higher value indicate worse outcome. |
Month 6.
|
|
KOOS-12
Délai: Month 6.
|
Knee injury and Osteoarthritis Outcome Score (KOOS)-12, range 12-60, higher value indicate worse outcome. |
Month 6.
|
|
Concomitant medication
Délai: Month 1, 3, 6, 9 and 12.
|
Concomitant medication |
Month 1, 3, 6, 9 and 12.
|
|
Tender and swollen joints
Délai: Month 1, 3, 6, 9 and 12.
|
Number of tender and swollen joints (range 0-30), higher values indicate more affected joints. |
Month 1, 3, 6, 9 and 12.
|
|
Physician-reported disease activity on a visual analogue scale
Délai: Month 1, 3, 6, 9 and 12.
|
Patient-reported disease activity on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Hand radiographs: Kellgren Lawrence
Délai: Month 6 and 12
|
Conventional radiographs: change in radiographic severity according to Kellgren-Lawrence scale, range 0-4 in each joint higher value indicate worse outcome. |
Month 6 and 12
|
|
Hand radiographs: Verbruggen-Veys anatomical phase scoring system
Délai: Month 6 and 12
|
Conventional radiographs: radiographic severity in finger joints according to Verbruggen-Veys anatomical phase scoring system, range 1-5; higher value indicate worse outcome. |
Month 6 and 12
|
|
Hand radiographs: OARSI atlas
Délai: Month 6 and 12
|
Conventional radiographs: rdiographic severity according to the Osteoarthritis Research Society International (OARSI) atlas for the presence/severity of osteophytes, joint space narrowing and erosions. |
Month 6 and 12
|
|
Hand MRI
Délai: Month 6
|
MRI of dominant hand: number of joints with synovitis and BMLs |
Month 6
|
|
Hand ultrasound
Délai: Month 1, 3, 6, 9 and 12.
|
Ultrasound: number of finger joints with synovial thickening and power Doppler signals. |
Month 1, 3, 6, 9 and 12.
|
|
Knee ultrasound
Délai: Month 6
|
Ultrasound: degree of synovitis in knee joints |
Month 6
|
|
Hip ultrasound
Délai: Month 6
|
Ultrasound: degree of synovitis in hip joints |
Month 6
|
|
Adverse events
Délai: Through study completion, maximum 12 months, in addition to 3 months after end of treatment.
|
Number of adverse events, serious adverse events, and withdrawals because of adverse events. |
Through study completion, maximum 12 months, in addition to 3 months after end of treatment.
|
Autres mesures de résultats
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Sub-study: biopsy of knee OA
Délai: Month 6
|
Change in synovial cellular composition and gene expression with single-cell RNA sequencing analyses; subgroup analyses, n=16 patients |
Month 6
|
|
Sub-study: knee pain on a visual analogue scale
Délai: Month 6
|
Self-reported knee pain previous 48 hours on a 0-100 mm scale at 6 months of treatment; higher value indicate worse outcome. |
Month 6
|
|
Question about blinding
Délai: Month 12
|
The participants are asked which treatment they think they have received |
Month 12
|
|
HADS
Délai: Month 6
|
Hospital Anxiety and Depression Scales (HADS), range 0-42, higher value indicate worse outcome. |
Month 6
|
|
PCS
Délai: Month 6
|
Pain catastrophizing scale, range 0-12, higher value indicate worse outcome. |
Month 6
|
|
PSQ
Délai: Month 6
|
Pain Sensitivity Questionnaire (PSQ), range 0-170, higher value indicate worse outcome. |
Month 6
|
|
Anchor questions for MCII and PASS
Délai: Month 6
|
Questions about perceived improvement and acceptable symptom state that will be used to define minimally clinically important improvement and patient acceptable symptom state for other questionnaires |
Month 6
|
|
ASES
Délai: Month 6
|
Arthritis Self Efficacy Scale (ASES), range 10-100, higher value indicate better outcome. |
Month 6
|
|
Pain sensitization
Délai: Month 6
|
Pain sensitization: Pressure Pain Thresholds (PPT) by digital algometer; temporal summation by punctate probes; Conditioned Pain Modulation (CPM) by blood pressure ischemic test. |
Month 6
|
|
Soluble biomarkers of extracellular matrix turnover
Délai: Month 6 and 12
|
Markers of collagen degradation (s-COMP, s-C1M, s-C2M, s-C3M, s-CTX1, sHA), collagen synthesis (s-proC2), aggrecan degradation (s-huARGS) and inflammation (s-calprotectin, s- vimentin, s-hsCRP and s-CRPM); Inflammatory cytokines (IL-1β, IL-1ra, IL-4, IL-6, IL-10, IL-12, IL-17, IL-18, IL-21, IFN-γ, TNF-α, VEGF, GM-CSF, CCL2, CCL3, CCL4, CXCL10) and hormones (leptin and resistin). |
Month 6 and 12
|
|
Omics
Délai: Month 6 and 12
|
Omics analyses of whole blood |
Month 6 and 12
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Les enquêteurs
Les enquêteurs
- Chaise d'étude: Tore K Kvien, MD, PhD, Professor Em.
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- DIA2020-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
The trialists and other study personnel that conceive of the study, and then plan, manage, monitor, analyze and publish it, will have access to IPD. Participants' identification code numbers are de-identified by replacing the original code number with a new random code number. Only the PI and project coordinator have access to this code.
The protocol, SAP, ICF, and CSR will be shared with regulatory agents as required.
Données/documents d'étude
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .